Works matching IS 00070920 AND DT 2018 AND VI 119 AND IP 9


Results: 17
    1
    2

    Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

    Published in:
    British Journal of Cancer, 2018, v. 119, n. 9, p. 1067, doi. 10.1038/s41416-018-0310-8
    By:
    • Wortman, B. G.;
    • Creutzberg, C. L.;
    • Putter, H.;
    • Jürgenliemk-Schulz, I. M.;
    • Jobsen, J. J.;
    • Lutgens, L. C. H. W.;
    • van der Steen-Banasik, E. M.;
    • Mens, J. W. M.;
    • Slot, A.;
    • Kroese, M. C. Stenfert;
    • van Triest, B.;
    • Nijman, H. W.;
    • Stelloo, E.;
    • Bosse, T.;
    • de Boer, S. M.;
    • van Putten, W. L. J.;
    • Smit, V. T. H. B. M;
    • Nout, R. A.;
    • for the PORTEC Study Group
    Publication type:
    Article
    3
    4
    5
    6

    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.

    Published in:
    British Journal of Cancer, 2018, v. 119, n. 9, p. 1075, doi. 10.1038/s41416-018-0271-y
    By:
    • Friedlander, Michael;
    • Matulonis, Ursula;
    • Gourley, Charlie;
    • du Bois, Andreas;
    • Vergote, Ignace;
    • Rustin, Gordon;
    • Scott, Clare;
    • Meier, Werner;
    • Shapira-Frommer, Ronnie;
    • Safra, Tamar;
    • Matei, Daniela;
    • Shirinkin, Vadim;
    • Selle, Frédéric;
    • Fielding, Anitra;
    • Lowe, Elizabeth S.;
    • McMurtry, Emma L.;
    • Spencer, Stuart;
    • Rowe, Philip;
    • Mann, Helen;
    • Parry, David
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Phenotype-independent DNA methylation changes in prostate cancer.

    Published in:
    British Journal of Cancer, 2018, v. 119, n. 9, p. 1133, doi. 10.1038/s41416-018-0236-1
    By:
    • Pellacani, Davide;
    • Droop, Alastair P.;
    • Frame, Fiona M.;
    • Simms, Matthew S.;
    • Mann, Vincent M.;
    • Collins, Anne T.;
    • Eaves, Connie J.;
    • Maitland, Norman J.
    Publication type:
    Article
    13

    Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

    Published in:
    British Journal of Cancer, 2018, v. 119, n. 9, p. 1086, doi. 10.1038/s41416-018-0235-2
    By:
    • Munster, Pamela;
    • Krop, Ian E.;
    • LoRusso, Patricia;
    • Ma, Cynthia;
    • Siegel, Barry A.;
    • Shields, Anthony F.;
    • Molnár, István;
    • Wickham, Thomas J.;
    • Reynolds, Joseph;
    • Campbell, Karen;
    • Hendriks, Bart S.;
    • Adiwijaya, Bambang S.;
    • Geretti, Elena;
    • Moyo, Victor;
    • Miller, Kathy D.
    Publication type:
    Article
    14
    15
    16

    Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).

    Published in:
    British Journal of Cancer, 2018, v. 119, n. 9, p. 1052, doi. 10.1038/s41416-018-0123-9
    By:
    • Romero-Laorden, Nuria;
    • Lozano, Rebeca;
    • Jayaram, Anuradha;
    • López-Campos, Fernando;
    • Saez, Maria I.;
    • Montesa, Alvaro;
    • Gutierrez-Pecharoman, Ana;
    • Villatoro, Rosa;
    • Herrera, Bernardo;
    • Correa, Raquel;
    • Rosero, Adriana;
    • Pacheco, María I.;
    • Garcés, Teresa;
    • Cendón, Ylenia;
    • Nombela, Ma Paz;
    • Van de Poll, Floortje;
    • Grau, Gala;
    • Rivera, Leticia;
    • López, Pedro P.;
    • Cruz, Juan-Jesús
    Publication type:
    Article
    17